| Detected | Trial | Change |
|---|---|---|
| 2026-05-30 | NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With… |
Trial sites expanded: 61 -> 64 locations |
| 2026-05-27 | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With… |
Primary endpoint(s) modified |
| 2026-05-27 | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With… |
Trial sites expanded: 37 -> 52 locations |
| 2026-05-27 | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With… |
date change Primary completion moved earlier: 2028-03 -> 2026-07 |
| 2026-05-27 | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With… |
date change Completion pushed: 2028-03 -> 2028-04 |
| 2026-05-14 | NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With… |
Trial sites reduced: 64 -> 61 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low… | Epithelial Ovarian Cancer | Recruiting |
| NCT07213804 | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With… | Ovarian Neoplasms | Recruiting |
| Phase 2 | |||
| NCT06365853 | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab… | Recurrent Ovarian Cancer | Recruiting |
| NCT06682988 | A Study to Assess Adverse Events and Change in Disease Activity in Participants With… | Advanced High-Grade Epithelial Ovarian Cancer | Recruiting |
| NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With… | Epithelial Ovarian Cancer | Recruiting |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | Ovary Cancer | Recruiting |
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment… | Ovarian Cancer | Recruiting |
| NCT04274426 | Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent… | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | Active, Not Recruiting |
| NCT03835819 | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial… | Endometrial Cancer | Active, Not Recruiting |